Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 4
2009 1
2012 2
2013 4
2014 2
2015 3
2016 5
2017 5
2018 13
2019 11
2020 14
2021 11
2022 6
2023 9
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Targeting therapy-persistent residual disease.
Sun X, Wu LF, Altschuler SJ, Hata AN. Sun X, et al. Among authors: hata an. Nat Cancer. 2024 Sep;5(9):1298-1304. doi: 10.1038/s43018-024-00819-9. Epub 2024 Sep 17. Nat Cancer. 2024. PMID: 39289594 Review.
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. Lin JJ, et al. Among authors: hata an. Cancer Discov. 2024 Sep 13:OF1-OF20. doi: 10.1158/2159-8290.CD-24-0231. Online ahead of print. Cancer Discov. 2024. PMID: 39269178
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer.
Murayama T, Mahadevan NR, Meador CB, Ivanova EV, Pan Y, Knelson EH, Tani T, Nakayama J, Ma X, Thai TC, Hung YP, Kim W, Watanabe H, Cai KQ, Hata AN, Paweletz CP, Barbie DA, Cañadas I. Murayama T, et al. Among authors: hata an. Cancer Res Commun. 2024 Sep 1;4(9):2399-2414. doi: 10.1158/2767-9764.CRC-24-0360. Cancer Res Commun. 2024. PMID: 39177280 Free PMC article.
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
El Zarif T, Meador CB, Qiu X, Seo JH, Davidsohn MP, Savignano H, Lakshminarayanan G, McClure HM, Canniff J, Fortunato B, Li R, Banwait MK, Semaan K, Eid M, Long H, Hung YP, Mahadevan NR, Barbie DA, Oser MG, Piotrowska Z, Choueiri TK, Baca SC, Hata AN, Freedman ML, Berchuck JE. El Zarif T, et al. Among authors: hata an. Clin Cancer Res. 2024 Sep 3;30(17):3798-3811. doi: 10.1158/1078-0432.CCR-24-0466. Clin Cancer Res. 2024. PMID: 38912901 Free PMC article.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
Takahashi M, Chong HB, Zhang S, Yang TY, Lazarov MJ, Harry S, Maynard M, Hilbert B, White RD, Murrey HE, Tsou CC, Vordermark K, Assaad J, Gohar M, Dürr BR, Richter M, Patel H, Kryukov G, Brooijmans N, Alghali ASO, Rubio K, Villanueva A, Zhang J, Ge M, Makram F, Griesshaber H, Harrison D, Koglin AS, Ojeda S, Karakyriakou B, Healy A, Popoola G, Rachmin I, Khandelwal N, Neil JR, Tien PC, Chen N, Hosp T, van den Ouweland S, Hara T, Bussema L, Dong R, Shi L, Rasmussen MQ, Domingues AC, Lawless A, Fang J, Yoda S, Nguyen LP, Reeves SM, Wakefield FN, Acker A, Clark SE, Dubash T, Kastanos J, Oh E, Fisher DE, Maheswaran S, Haber DA, Boland GM, Sade-Feldman M, Jenkins RW, Hata AN, Bardeesy NM, Suvà ML, Martin BR, Liau BB, Ott CJ, Rivera MN, Lawrence MS, Bar-Peled L. Takahashi M, et al. Among authors: hata an. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22. Cell. 2024. PMID: 38653237
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Baca SC, et al. Among authors: hata an. Nat Med. 2024 Mar;30(3):907. doi: 10.1038/s41591-023-02735-4. Nat Med. 2024. PMID: 38049623 Free PMC article. No abstract available.
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D. Haratake N, et al. Among authors: hata an. J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3. J Thorac Oncol. 2024. PMID: 37924972 Free article.
96 results